Global Sandhoff Disease Therapeutics Market by Type (AL601, CC010, DUO01, MTHEXB), By Application (Clinic, Hospital) And By Region (North America, Latin America Europe Asia Pacific and Middle East & Africa) Forecast From 2021 To 2030. The Market is mainly driven by the increase in prevalence of Sandhoff disease with a global range from 1:100000 to 1:50000. It also takes into account that insufficient treatment options are available for patients with the condition due to lack of research on the subject. This has resulted in an increase in market opportunities for companies and research firms since there are only a few treatments available for people suffering from Sandhoff disease.
This research is a global market forecast for Sandhoff disease therapeutics from 2021-2030. It provides in-depth analysis of the market, with data from 2016 to 2026 and forecast to 2030. In this study, an in-depth analysis will be done on factors such as drivers and restraints in the market. The study also covers detailed competitive landscape for the companies operating in this market. This includes their products, strategies adopted by them and other initiatives that they have taken which has helped them grow over time. The scope of this study is limited to Sandhoff disease therapeutics only and does not cover other therapeutic segments or treatment options available for people suffering from Sandhoff disease.
The CAGR during the period covered by this research (2016-2026) stands at 10%. This indicates significant growth potentials for companies investing now in developing new therapies or developing different treatment options for patients suffering from Sandhoff disease.
Sandhoff disease is an inherited disorder caused by the absence of beta-hexosaminidase, a lysosomal enzyme that breaks down certain complex sugars, such as GM2 ganglioside, affecting both the CNS and peripheral tissues. This disease mostly affects infants and children under two years old with a median age of 15 months at diagnosis. The clinical symptoms are varied and can be mild or severe depending on the type of mutation responsible for Sandhoff disease in each individual patient. Symptoms include progressive loss of motor skills and mental retardation, behavioral changes like insomnia and agitation that can lead to self injury or violence against others due to frustration or anger from being unable to communicate their needs, seizures, blindness due to optic atrophy in about 30% cases which can lead to blindness if untreated, an enlarged liver (hepatomegaly), enlarged spleen (splenomegaly) which leads to difficulty breathing due to compression on respiratory structures from abdominal organs pressing against the diaphragm when lying down, enlarged lungs (pulmonary hypertrophy), recurrent bacterial infections like meningitis because there is decreased cell-mediated immunity leading to an increased frequency of opportunistic infections with Burkholderia pseudomallei among others; one unique symptom is retinopathy which causes photophobia and visual impairment in about 10% cases where there are chronic lesions on retina secondary either direct extension from brain lesions or through choroid vasculature damage.
The global Sandhoff Disease therapeutics market was valued at US$2240 million in 2017 increasing at a CAGR over 7%. The North America region dominated the market with around 60% share owing mainly because it has better healthcare infrastructure than other developing regions; this makes it easier for patients suffering from Sandhoff Disease across North America region have access proper treatment facilities providing.
Industry Growth Insights published a new data on “Sandhoff Disease Therapeutics Market”. The research report is titled “Sandhoff Disease Therapeutics Market research by Types (ALD-601, CCP-010, DUOC-01, MTf-HEXB, Others), By Applications (Clinic, Hospital, Others), By Players/Companies Bioasis Technologies Inc, Nuo Therapeutics Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sandhoff Disease Therapeutics Market Research Report
By Type
ALD-601, CCP-010, DUOC-01, MTf-HEXB, Others
By Application
Clinic, Hospital, Others
By Companies
Bioasis Technologies Inc, Nuo Therapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Sandhoff Disease Therapeutics Market Report Segments:
The global Sandhoff Disease Therapeutics market is segmented on the basis of:
Types
ALD-601, CCP-010, DUOC-01, MTf-HEXB, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bioasis Technologies Inc
- Nuo Therapeutics Inc
Highlights of The Sandhoff Disease Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ALD-601
- CCP-010
- DUOC-01
- MTf-HEXB
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sandhoff Disease Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sandhoff disease therapeutics is a term used to describe any drug or therapy that is being developed specifically for the treatment of Sandhoff disease.
Some of the key players operating in the sandhoff disease therapeutics market are Bioasis Technologies Inc, Nuo Therapeutics Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sandhoff Disease Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sandhoff Disease Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sandhoff Disease Therapeutics Market - Supply Chain
4.5. Global Sandhoff Disease Therapeutics Market Forecast
4.5.1. Sandhoff Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sandhoff Disease Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sandhoff Disease Therapeutics Market Absolute $ Opportunity
5. Global Sandhoff Disease Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sandhoff Disease Therapeutics Market Size and Volume Forecast by Type
5.3.1. ALD-601
5.3.2. CCP-010
5.3.3. DUOC-01
5.3.4. MTf-HEXB
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sandhoff Disease Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sandhoff Disease Therapeutics Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sandhoff Disease Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sandhoff Disease Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sandhoff Disease Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sandhoff Disease Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sandhoff Disease Therapeutics Demand Share Forecast, 2019-2026
9. North America Sandhoff Disease Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sandhoff Disease Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sandhoff Disease Therapeutics Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sandhoff Disease Therapeutics Market Size and Volume Forecast by Type
9.7.1. ALD-601
9.7.2. CCP-010
9.7.3. DUOC-01
9.7.4. MTf-HEXB
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sandhoff Disease Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Sandhoff Disease Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sandhoff Disease Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sandhoff Disease Therapeutics Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sandhoff Disease Therapeutics Market Size and Volume Forecast by Type
10.7.1. ALD-601
10.7.2. CCP-010
10.7.3. DUOC-01
10.7.4. MTf-HEXB
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sandhoff Disease Therapeutics Demand Share Forecast, 2019-2026
11. Europe Sandhoff Disease Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sandhoff Disease Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sandhoff Disease Therapeutics Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sandhoff Disease Therapeutics Market Size and Volume Forecast by Type
11.7.1. ALD-601
11.7.2. CCP-010
11.7.3. DUOC-01
11.7.4. MTf-HEXB
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sandhoff Disease Therapeutics Demand Share, 2019-2026
12. Asia Pacific Sandhoff Disease Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sandhoff Disease Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sandhoff Disease Therapeutics Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sandhoff Disease Therapeutics Market Size and Volume Forecast by Type
12.7.1. ALD-601
12.7.2. CCP-010
12.7.3. DUOC-01
12.7.4. MTf-HEXB
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sandhoff Disease Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Sandhoff Disease Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sandhoff Disease Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sandhoff Disease Therapeutics Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sandhoff Disease Therapeutics Market Size and Volume Forecast by Type
13.7.1. ALD-601
13.7.2. CCP-010
13.7.3. DUOC-01
13.7.4. MTf-HEXB
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sandhoff Disease Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Sandhoff Disease Therapeutics Market: Market Share Analysis
14.2. Sandhoff Disease Therapeutics Distributors and Customers
14.3. Sandhoff Disease Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bioasis Technologies Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Nuo Therapeutics Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
